A carregar...
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer
A phase II trial in metastatic breast cancer (MBC) (NO16853) failed to show noninferiority (progression-free survival, PFS) of capecitabine 825 mg/m(2) plus docetaxel 75 mg/m(2) to the registered capecitabine dose of 1,250 mg/m(2) plus docetaxel 75 mg/m(2). We developed a modeling framework based on...
Na minha lista:
Main Authors: | , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Nature Publishing Group
2012
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3600724/ https://ncbi.nlm.nih.gov/pubmed/23835839 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2012.20 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
A carregar...